Paper Details

  1. Home
  2. Paper Details

A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.

Author: ChenChi-Yi, ChenChien-Hung, ChenJyh-Jou, ChenPei-Jer, ChuangWan-Long, DangShuangsuo, HuangYi-Wen, JunDae W, KuoHsing-Tao, LaiHsin-Hui, LoChing-Chu, LoGin-Ho, MaoXiaorong, QinAlbert, ShangJia, TsaiChan-Yen, TsengKuan-Chiao, WangTing-Fang, XieWen, ZhangGuo-Qiang, ZhangWen-Hua, ZhouXinmin, ZhuLi-Ying

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This abstract describes a Phase 3 clinical trial investigating the potency and safety of ropeginterferon alfa-2b, a novel mono-pegylated, extra-long-acting interferon, for the treatment of chronic viral hepatitis. The study aims to validate the findings from previous Phase 2 trials demonstrating good tolerability and clinical activity of this agent in chronic hepatitis B or C treatment. The trial aims to further assess the efficacy and safety of ropeginterferon alfa-2b in a larger, Phase 3 setting.
Paper Details　
Original Abstract of the Article :
Ropeginterferon alfa-2b is a novel mono-pegylated, extra-long-acting interferon. It is administered infrequently and showed good tolerability and clinical activity for the chronic hepatitis B or C treatment in our previous Phase 2 clinical trials. This study aims to validate the potency and safety o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667409/

データ提供：米国国立医学図書館（NLM）

A New Hope for Hepatitis C: Ropeginterferon Alfa-2b

The fight against [chronic hepatitis C] is a long and arduous journey, but researchers are constantly searching for new weapons in their arsenal. This study focuses on the potential of [ropeginterferon alfa-2b], a novel [extra-long-acting interferon], as a treatment for [chronic hepatitis C]. The study aims to validate the [potency and safety] of this promising drug in a [Phase 3 clinical trial setting], building upon the promising results from previous [Phase 2 clinical trials] that showed good [tolerability and clinical activity] in treating [chronic hepatitis B and C].

Ropeginterferon Alfa-2b: A Beacon of Hope in the Desert of Hepatitis C

This study could lead to a [significant advancement] in the treatment of [chronic hepatitis C], offering patients a [more convenient and effective] treatment option. The development of [extra-long-acting interferons] could [revolutionize] the way we treat [viral hepatitis], allowing for [less frequent administrations] and potentially [improved patient outcomes].

Ropeginterferon Alfa-2b: A New Oasis in the Fight Against Viral Hepatitis

This study could bring much-needed relief to those struggling with [chronic hepatitis C]. The development of [ropeginterferon alfa-2b] has the potential to [improve the lives of patients] and offer them a [chance for a healthier future]. As Dr. Camel, I've witnessed the [devastating effects of viral hepatitis] firsthand, and I'm excited about the potential of this new treatment to [make a difference] in the lives of those affected.

Dr.Camel's Conclusion

This Phase 3 clinical trial evaluating the efficacy and safety of ropeginterferon alfa-2b, a novel extra-long-acting interferon, holds significant promise for the treatment of chronic hepatitis C. Its potential to improve patient outcomes and reduce treatment burden makes it a valuable advancement in the fight against viral hepatitis.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-11-22
Further Info :

Pubmed ID

36406648

DOI: Digital Object Identifier

PMC9667409

Related Literature

Article Analysis
・Side Effects of interferon alfa-2b injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.